Patients Aged 65-85 (Both Included)DIALCATNCT03578991
Diabetes as an Accelerator of Cognitive Impairment and Alzheimer's Disease
A study testing Smart pillbox and Interactive digital platform in people with Patients Aged 65-85 (Both Included) and Diagnosed of Mild Cognitive Impairment, run by Parc Sanitari Pere Virgili at 8 sites in Spain.
Trial summary
This randomized controlled trial is aimed at studying the effects of an eHealth intervention on improving metabolic control and other cardiovascular risk factors (obesity, lipidic profile and hypertension) as the approach to prevent or delay the process of cognitive impairment, and to reduce conversion rates to… Read more about this study
- Who is it for?
- Ages 65 to 85 years
- Conditions the study is for
- Patients Aged 65-85 (Both Included), Diagnosed of Mild Cognitive Impairment, Diagnosed of Type 2 Diabetes in Active Treatment (Hypoglycemic Agents) for a Period ≥5 Years
- What is being tested?
- Smart pillbox and Interactive digital platform
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 54 participants
- Where
- 8 sitesSpain
- Study dates
- 1 Jul 2019to 15 Apr 2020
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 to 85 years
- All sexes
- No healthy volunteers
- Older adult
Who may be able to join
- Patients diagnosed of diabetes mellitus type 2 with time evolution ⋝5 years.
- Age between 65 and 85 years old (both included).
- Ability to read and write.
- Active treatment with hypoglycemic agents.
- Diagnosed with mild cognitive impairment.
Who cannot join
- Familiar history of Alzheimer's' disease.
- Patients with any type of dementia.
- History of neurological or psychiatric conditions not stabilized that can substantially affect cognition.
- Severe metabolic or systemic disease that affects the cognitive state. This includes:
- Unstable acute cardiovascular disease.
- Renal failure with glomerular filtration rate <30 ml/min/m2.
Show all 23Show fewer
- Decompensated cirrhosis or liver failure.
- Untreated hypothyroidism or vitamin B12 deficiency. If known.
- Active cancer or chemotherapy treatment the previous year.
- Treatment with drugs that alter the cognitive state, for example:
- Antipsychotic.
- Daily consumption of opioids.
- Benzodiazepines (BZD) long action (for example Diazepam). Benzodiazepines (BZD) short-acting at high doses such as Alprazolam at doses greater than 1 mg / day; Lorazepam at doses greater than 1 mg / day and Lormetazepam at doses greater than 1 mg / day.
- Fentanil patches in doses greater than 2.5 mg every 72 h.
- Gabapentin in doses greater than 600 mg / day.
- Pregabalin in doses greater than 50 mg / day.
- Amitriptyline in doses greater than 25 mg / day.
- Limitations of mobility that can avoid or restrict the application or evaluation of the intervention.
- Patients with other types of diabetes: diabetic mellitus type 1, LADA; MODY
- Unstable advanced diabetic retinopathy
- Patients with serious uncorrected sensory deficits that make assessment impossible (blindness, deafness).
- Patients with access to other online platforms for patients.
- Patients with access to other intelligent electronic dispensing devices for improved adherence to treatment.
Trial locations and contacts
8 sites in 1 country.
8 sites in 1 country
Spain8 sites
Parc Sanitari Pere Virgili
Barcelona, 08023
LambdaLoopers
Barcelona, 08034
University Hospital Vall d'Hebron - Vall d'Hebron Institute of Research
Barcelona, 08035
Fundació Privada Hospital Asil de Granollers (HAG)
Granollers, Barcelona, 08402
Fundació Althaia (FA)
Manresa, Barcelona, 08243
Fundació Recerca Mútua Terrassa (FMT)
Terrassa, Barcelona, 08221
Consorci Sanitari de Terrassa (CST)
Terrassa, Barcelona, 08227
Consorci Hospitalari de Vic (CHV)
Vic, Barcelona, 08500
About this study
Official title: Diabetes as an Accelerator of Cognitive Impairment and Alzheimer's Disease: Comprehensive Approach and Adherence to Treatment: DIALCAT Project.
This randomized controlled trial is aimed at studying the effects of an eHealth intervention on improving metabolic control and other cardiovascular risk factors (obesity, lipidic profile and hypertension) as the approach to prevent or delay the process of cognitive impairment, and to reduce conversion rates to Alzheimer's disease (AD) in a sample of patients diagnosed of type 2 diabetes mellitus (T2D) and with mild cognitive impairment (MCI).
For these purposes, the standard clinical treatment for this type of patients will be compared with two types of interventions (parallel groups): one aimed at promoting adherence to treatment through the use of a smart pillbox; and the other intervention will be based on the use of the smart pillbox plus and interactive digital platform allowing communication between patients and caregivers with healthcare professionals. Both interventions are targeted to improve adherence to treatment.
The hypothesis is that the rate of conversion from MCI to AD will be higher in the control group than in the intervention groups (higher conversion rates are expected in control group, followed by the smart pillbox group, and lower conversion rates are expected in the group using the interactive digital platform and the smart pillbox).
Read the detailed description
The objective of the DIALCAT randomized controlled trial is to study the effects of an eHealth intervention (smart pillbox, digital platform) on the progression of cognitive impairment evaluated by means of a neuropsychological examination, in a sample of elderly patients with type II diabetes (T2D) and mild cognitive impairment (MCI). As secondary goals, this research is intended to:
- Assess if the intervention improves the metabolic control of the study sample.
- Evaluate the effects of the intervention on the conversion rate (yes vs. no) from MCI to Alzheimer's' disease (AD).
- Compare the effectiveness of the interventions to reduce functional decline (quantified by a battery of neuropsychological tests [see detailed description below]) and the conversion rate to AD.
- Identify the clinical and analytical predictors (biomarkers) of conversion from MCI to AD.
To this purposes, a total of 174 T2D patients with MCI (MMSE≥24) will be recruited with a 18-month follow-up. Eligible patients will be randomized in a 1:1:1 ratio in one of the arms of the RCT (for randomization, a sex-by-sex-swapped sequence and the ApoE genotype will be used). The three groups will receive the following interventions:
Arm 1: T2D patients (n = 58) with MCI, receiving treatment as usual (TAU) by their primary care physician/endocrinologist.
Arm 2: T2D patients (n = 58) with MCI, receiving TAU and using a smart pillbox that allows to monitor adherence to treatment.
Arm 3: T2D patients (n = 58) with MCI, receiving TAU, using the smart pillbox and receiving periodic feedback on their metabolic control and how to improve it by an endocrinologist via a digital platform.
Since it is expected that the different factors related to the intervention will have an additive or synergistic effect, the hypothesis is that the cognitive impairment and progression of MCI to AD would be higher in arm 1, followed by arm 2 and, finally, arm 3.
- Conditions
- Patients Aged 65-85 (Both Included), Diagnosed of Mild Cognitive Impairment, Diagnosed of Type 2 Diabetes in Active Treatment (Hypoglycemic Agents) for a Period ≥5 Years
- Being tested
- Smart pillbox, Interactive digital platform
- Keywords
- Type 2 diabetes mellitus, Mild cognitive impairment, Alzheimer disease, Intervention, Clinical trial, mHealth, Smart electronic pillbox, Interactive digital platform
- Medical subject headings
- Diabetes Mellitus, Type 2, Cognitive Dysfunction, Alzheimer Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Smart pillboxDevice
The smart electronic pillbox will monitor adherence to pharmacological treatment by means of registering time of medications intake. It will incorporate visual and auditory reminders for taking medications (all of them, being or not being inside the dispenser such as insulin or eye drops). The dispenser will also have sensors and alarms to ensure the proper preservation of the medicines contained. The dispenser will be recharged weekly by a trained pharmacist. Each dispenser will be identified unequivocally with one user, and it will be interconnected with a mobile application (app).
Interactive digital platformOther
The digital interactive platform will allow communication between patients and caregivers and healthcare professionals. Its aims are to provide feedback and guidelines on treatment adherence and also, on how to better optimize treatment on cardiovascular risk factors. The platform will inform about medication dosages and intake schedule, healthy lifestyles related to diabetes, occurrence of adverse events, and it will also monitor patients' glycemic control. In this sense, several alarms are programmed to warn caregivers or even healthcare professionals when the patient has hyperglycemia or hypoglycaemia. The platform will provide too guidelines on how to treat hypo or hyperglycemia as well as most common adverse events, and it will describe reasons to have suffered it.
| Study group | Role | What they receive |
|---|---|---|
| Arm 1 | No intervention | Control group - Treatment as usual: Type 2 diabetic patients with mild cognitive impairment who will receive the standard clinical treatment recommended by their primary care physician/endocrinologist. |
| Arm 2 | Experimental | Intervention - Smart pillbox:
Type 2 diabetic patients with mild cognitive impairment receiving the standard clinical treatment recommended by their primary care physician/endocrinologist, plus the use of a smart pillbox. Receives: Device: Smart pillbox |
| Arm 3 | Experimental | Intervention - Smart pillbox \& Interactive digital platform:
Description: Type 2 diabetic patients with mild cognitive impairment receiving the standard clinical treatment recommended by their primary care physician/endocrinologist, plus the use of a smart pillbox and an interactive digital platform. Receives: Device: Smart pillbox; Other: Interactive digital platform |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change of score obtained in the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).
The main variable of the study will be the score obtained in the RBANS in the different assessment periods. The RBANS was designed to be administered in adult population between 20 and 89 years. It is sensitive to the detection of cognitive disorder in degenerative and non-degenerative pathology. This battery evaluates 5 functions, by means of 12 subtests: 1) attention (repetition of digits and numerical key), 2) language (designation of drawings and semantic fluency), 3) visual-espacial / constructive ability (copy a figure and orientation of lines), 4) immediate memory (word learning and memory of the story) and 5) deferred memory (record of the list, word recognition, record of the story, record of the figure). The RBANS is a short battery (time of administration ≦30 minutes), and has two parallel forms of evaluation (forms A and B) to avoid the effect of learning.
Measured: At baseline (at the moment of the study enrollment), and an average of 18 months after enrollment.
Secondary outcomes (19)
Cardiovascular risk factor: Hypertension.
Hypertension (mmHg) will be registered. Both pressures will be assessed (systolic and diastolic). This information will be extracted from clinical records.
Measured: At baseline (at the moment of the study enrollment), and an average of 18 months after enrollment.
Cardiovascular risk factor: Obesity.
Body Mass Index (BMI) will be calculated. Weight and height will be combined to calculate and report BMI. This information will be extracted from clinical records.
Measured: At baseline (at the moment of the study enrollment), and an average of 18 months after enrollment.
Cardiovascular risk factor: Dyslipidemia.
Dyslipidemia (md/dL) will be screened. This information will be extracted from clinical records.
Measured: At baseline (at the moment of the study enrollment), and an average of 18 months after enrollment.
Degree of diabetes control.
For the degree of diabetes control will be registered from blood tests level of glycosylated hemoglobin, plasma glucose and insulinemia in fasting.
Measured: At baseline (at the moment of the study enrollment), at 9 and an average of 18 months after enrollment.
Usal medication.
Medication for hypertension, dyslipidemia and diabetes will be extracted from clinical records. Type of treatment, dosage, route of administration, frequency and changes in medication will be registered and listed.
Measured: At baseline (at the moment of the study enrollment), and an average of 18 months after enrollment.
Presence of micro and macrovascular complications.
The presence and severity of retinopathy, nephropathy (microalbuminuria levels), polyneuropathy and/or cardiovascular disease (specifically, ischemic heart disease, cerebrovascular accident or peripheral arterial disease) will be extracted from medical records.
Measured: At baseline (at the moment of the study enrollment), and an average of 18 months after enrollment.
Presence and severity of hypoglycemia.
Patients will be asked about the presence and severity of hypoglycaemia by answering a self-reported measure developed ad hoc by the Endocrinology Service of the Vall d'Hebron University Hospital. Patients with ambulatory insulinization will have a glucometer which will be reviewed by the doctor at each visit. Wil considerate hypoglycemia when the capillary glucose levels are between 70-50 mg/dl, and hypoglycemia when the levels are <50 mg/dl. All hypoglycemia will be registered.
Measured: At baseline (at the moment of the study enrollment), at 4, 9, 13 and an average of 18 months after enrollment.
Lipid profile and renal and hepatic function.
Levels of low-density lipoprotein cholesterol (mg/dl), high-density lipoprotein cholesterol (mg/dl), triglycerides (mg/dl), creatinine (mg/dl), glomerular filtration (ml/min/m2), aspartate aminotransferase (U/L) and alanine aminotransferase (U/L) will be registered by means of blood tests. A final composite (bad vs. good lipidic profile and hepatic function) will be calculated based on these parameters.
Measured: At baseline (at the moment of the study enrollment), at 9 and an average of 18 months after enrollment.
Biomarkers (serum and DNA).
Biomarkers (serum and DNA) will be registered by means of blood tests.
Measured: At baseline (at the moment of the study enrollment), and an average of 18 months after enrollment.
Short Physical Performance Battery test (SPPB).
The SPPB is a group of measures that combines the results of the gait speed, chair stand and balance tests. It has been used as a predictive tool for possible disability and can aid in the monitoring of function in older people. The scores range from 0 (worst performance) to 12 (best performance). The SPPB has been shown to have predictive validity showing a gradient of risk for mortality, nursing home admission, and disability.
Measured: At baseline (at the moment of the study enrollment), and an average of 18 months after enrollment.
Hachinski Scale (HS).
The HS allows differentiation of degenerative vascular dementias. A score ≥7 suggests vascular dementia and a score <4 points suggests Alzheimer's disease. The validity of this scale has been investigated in several clinical studies, considering a specificity and sensitivity of the order of 70-80%.
Measured: At baseline (at the moment of the study enrollment), and an average of 18 months after enrollment.
Blessed Dementia Rating Scale (BDRS).
The BDRS allows to screen for MCI and dementia in the elderly by quantifying performance in daily life activities by means of 28 items. The sensitivity according to the Cambridge Mental Disorders of the Elderly Examination (CAMCOG) was 90% with a specificity of 76%. A score >15 suggests moderate or severe dementia; a score between 4-14 suggests suspicion of dementia.
Measured: At baseline (at the moment of the study enrollment), at, 4, 9, 13 and an average of 18 months after enrollment.
Geriatric Depression Scale (GDS; 15-item short form).
The Geriatric Depression Scale (GDS) is one of the most widely used instrument for the screening of depression in the elderly. This auto-administered questionnaire have shown to be sensitive to depression among elderly persons suffering from mild to moderate dementia and physical illness. The 15-item short version of the GDS (GDS-15) is considered useful in situations where economy of time is required. The score of the GDS-15 ranges from 0 to 15. A score of zero to four is considered to be within the normal range, five to nine indicates mild depression, and a score of 10 or more indicates moderate to severe depression.
Measured: At baseline (at the moment of the study enrollment), at, 4, 9, 13 and an average of 18 months after enrollment.
Schwab and England Activities of Daily Living Scale (SE-ADL).
This scale describing the capacity for daily living shown by a patient with Parkinson's Disease and can be used for other conditions. This scale uses a percentage system to assign levels of independence and dependence, in which 100 percent represents complete independence and 0 percent complete dependence (bedridden).
Measured: At baseline (at the moment of the study enrollment), at 4, 9, 13 and an average of 18 months after enrollment.
Montreal Cognitive Assessment (MOCA).
The MOCA is a cognitive screening test for MCI and Early Alzheimer's disease. According to the validation study, the sensitivity and specificity of the MOCA for detecting MCI were 90% and 87% respectively. Is a one-page 30-point test administered in approximately 10 minutes.
Measured: At baseline (at the moment of the study enrollment), and an average of 18 months after enrollment.
Mini-Mental State Examination (MMSE).
The MMSE is a brief cognitive test that assesses several cognitive domains, such as orientation, attention, concentration, memory, language, and constructional abilities. For the MMSE the sensitivity was 0.87 and 0.82 for specificity.
Measured: At baseline (at the moment of the study enrollment), and an average of 18 months after enrollment.
Memory failure in everyday life questionnaire (MFE).
The MFE is one of the most widely-used instruments to assess memory failures in daily life to detect cognitive complaints. It consists of 28 items and has revealed a sensitivity of 83.1% with a specificity of 81.8% and positive predictor vale of 95.3%.
Measured: At baseline (at the moment of the study enrollment), at 4, 9, 13 and an average of 18 months after enrollment.
The Functional Social Support Questionnaire (DUKE-UNC-11).
The DUKE-UNC-11 allows to measure the patient perception of the amount and type of personal social support. It was originally developed to measure social support in family medicine patients. Cut-off lower than 32 indicates low self-perceived social support.
Measured: At baseline (at the moment of the study enrollment), at 4, 9, 13 and an average of 18 months after enrollment.
The Resource Utilization in Dementia (RUD).
The RUD instrument is valid for assessing healthcare resource utilization among older adults with dementia and their caregivers, and time spent on formal and informal care by caregivers.
Measured: At baseline (at the moment of the study enrollment), at 9 and an average of 18 months after enrollment.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jul 2018
- Study start1 Jul 2019
- Primary completion15 Apr 2020
- Study completion15 Apr 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Patients Aged 65-85 (Both Included)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 54 participants (actual)
Sponsor and investigators
- Lead sponsor
- Parc Sanitari Pere Virgili
- Sponsor type
- University, hospital or other
- Collaborators
- Hospital Vall d'Hebron, Consorci Sanitari de Terrassa, Fundació Recerca Mútua Terrassa (FMT), Clínica Universitària de la Fundació Universitària del Bages (FUB), Althaia Xarxa Assistencial Universitària de Manresa, Fundació Privada Hospital Asil de Granollers (HAG), Consorci Hospitalari de Vic, LambdaLoopers, Universitat Politècnica de Catalunya, Leitat, Mixestat, Meditecnologia
- Responsible party
- Sponsor
- Investigators
- Marco Inzitari, MD, PhD, Principal investigator, Parc Sanitari Pere Virgili
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03578991
- Sponsor's protocol ID
- DIALCAT COMRDI-B64574221423350
- Other IDs
- COMRDI B64574221423350
- Acronym
- DIALCAT
- Status last verified
- Aug 2020
- First submitted
- 20 Jun 2018
- Last updated
- 14 Aug 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Aug 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Diabetes as an Accelerator of Cognitive Impairment and Alzheimer's Disease: Comprehensive Approach and Adherence to Treatment: DIALCAT Project.
- ClinicalTrials.gov ID
- NCT03578991
- Acronym / sponsor ID
- DIALCAT / DIALCAT COMRDI-B64574221423350
- Conditions
- Patients Aged 65-85 (Both Included), Diagnosed of Mild Cognitive Impairment, Diagnosed of Type 2 Diabetes in Active Treatment (Hypoglycemic Agents) for a Period ≥5 Years
- Keywords
- Type 2 diabetes mellitus, Mild cognitive impairment, Alzheimer disease, Intervention, Clinical trial, mHealth, Smart electronic pillbox, Interactive digital platform
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 54 participants (actual)
- Lead sponsor
- Parc Sanitari Pere VirgiliUniversity, hospital or other
- Collaborators
- Hospital Vall d'Hebron, Consorci Sanitari de Terrassa, Fundació Recerca Mútua Terrassa (FMT), Clínica Universitària de la Fundació Universitària del Bages (FUB), Althaia Xarxa Assistencial Universitària de Manresa, Fundació Privada Hospital Asil de Granollers (HAG), Consorci Hospitalari de Vic, LambdaLoopers, Universitat Politècnica de Catalunya, Leitat, Mixestat, Meditecnologia
- Study start
- 1 Jul 2019 (actual)
- Primary completion
- 15 Apr 2020 (actual)
- Study completion
- 15 Apr 2020 (actual)
- First posted
- 6 Jul 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This randomized controlled trial is aimed at studying the effects of an eHealth intervention on improving metabolic control and other cardiovascular risk factors (obesity, lipidic profile and hypertension) as the approach to prevent or delay the process of cognitive impairment, and to reduce conversion rates to Alzheimer's disease (AD) in a sample of patients diagnosed of type 2 diabetes mellitus (T2D) and with mild cognitive impairment (MCI).
For these purposes, the standard clinical treatment for this type of patients will be compared with two types of interventions (parallel groups): one aimed at promoting adherence to treatment through the use of a smart pillbox; and the other intervention will be based on the use of the smart pillbox plus and interactive digital platform allowing communication between patients and caregivers with healthcare professionals. Both interventions are targeted to improve adherence to treatment.
The hypothesis is that the rate of conversion from MCI to AD will be higher in the control group than in the intervention groups (higher conversion rates are expected in control group, followed by the smart pillbox group, and lower conversion rates are expected in the group using the interactive digital platform and the smart pillbox).
Detailed description
The objective of the DIALCAT randomized controlled trial is to study the effects of an eHealth intervention (smart pillbox, digital platform) on the progression of cognitive impairment evaluated by means of a neuropsychological examination, in a sample of elderly patients with type II diabetes (T2D) and mild cognitive impairment (MCI). As secondary goals, this research is intended to:
- Assess if the intervention improves the metabolic control of the study sample.
- Evaluate the effects of the intervention on the conversion rate (yes vs. no) from MCI to Alzheimer's' disease (AD).
- Compare the effectiveness of the interventions to reduce functional decline (quantified by a battery of neuropsychological tests [see detailed description below]) and the conversion rate to AD.
- Identify the clinical and analytical predictors (biomarkers) of conversion from MCI to AD.
To this purposes, a total of 174 T2D patients with MCI (MMSE≥24) will be recruited with a 18-month follow-up. Eligible patients will be randomized in a 1:1:1 ratio in one of the arms of the RCT (for randomization, a sex-by-sex-swapped sequence and the ApoE genotype will be used). The three groups will receive the following interventions:
Arm 1: T2D patients (n = 58) with MCI, receiving treatment as usual (TAU) by their primary care physician/endocrinologist.
Arm 2: T2D patients (n = 58) with MCI, receiving TAU and using a smart pillbox that allows to monitor adherence to treatment.
Arm 3: T2D patients (n = 58) with MCI, receiving TAU, using the smart pillbox and receiving periodic feedback on their metabolic control and how to improve it by an endocrinologist via a digital platform.
Since it is expected that the different factors related to the intervention will have an additive or synergistic effect, the hypothesis is that the cognitive impairment and progression of MCI to AD would be higher in arm 1, followed by arm 2 and, finally, arm 3.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Arm 1 | No intervention | –Control group - Treatment as usual: Type 2 diabetic patients with mild cognitive impairment who will receive the standard clinical treatment recommended by their primary care physician/endocrinologist. |
| Arm 2 | Experimental | Device: Smart pillboxIntervention - Smart pillbox: Type 2 diabetic patients with mild cognitive impairment receiving the standard clinical treatment recommended by their primary care physician/endocrinologist, plus the use of a smart pillbox. |
| Arm 3 | Experimental | Device: Smart pillbox, Other: Interactive digital platformIntervention - Smart pillbox \& Interactive digital platform: Description: Type 2 diabetic patients with mild cognitive impairment receiving the standard clinical treatment recommended by their primary care physician/endocrinologist, plus the use of a smart pillbox and an interactive digital platform. |
Who may qualify
- Ages
- 65 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
Key inclusion criteria (5 listed)
- Patients diagnosed of diabetes mellitus type 2 with time evolution ⋝5 years.
- Age between 65 and 85 years old (both included).
- Ability to read and write.
- Active treatment with hypoglycemic agents.
- Diagnosed with mild cognitive impairment.
Key exclusion criteria (23 listed)
- Familiar history of Alzheimer's' disease.
- Patients with any type of dementia.
- History of neurological or psychiatric conditions not stabilized that can substantially affect cognition.
- Severe metabolic or systemic disease that affects the cognitive state. This includes:
- Treatment with drugs that alter the cognitive state, for example:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Smart pillboxThe smart electronic pillbox will monitor adherence to pharmacological treatment by means of registering time of medications intake. It will incorporate visual and auditory reminders for taking medications (all of them, being or not being inside the dispenser such as insulin or eye drops). The dispenser will also have sensors and alarms to ensure the proper preservation of the medicines contained. The dispenser will be recharged weekly by a trained pharmacist. Each dispenser will be identified unequivocally with one user, and it will be interconnected with a mobile application (app). | Device | Arm 2, Arm 3 |
| Interactive digital platformThe digital interactive platform will allow communication between patients and caregivers and healthcare professionals. Its aims are to provide feedback and guidelines on treatment adherence and also, on how to better optimize treatment on cardiovascular risk factors. The platform will inform about medication dosages and intake schedule, healthy lifestyles related to diabetes, occurrence of adverse events, and it will also monitor patients' glycemic control. In this sense, several alarms are programmed to warn caregivers or even healthcare professionals when the patient has hyperglycemia or hypoglycaemia. The platform will provide too guidelines on how to treat hypo or hyperglycemia as well as most common adverse events, and it will describe reasons to have suffered it. | Other | Arm 3 |
Primary outcome
Change of score obtained in the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).
Time frame: At baseline (at the moment of the study enrollment), and an average of 18 months after enrollment.
The main variable of the study will be the score obtained in the RBANS in the different assessment periods. The RBANS was designed to be administered in adult population between 20 and 89 years. It is sensitive to the detection of cognitive disorder in degenerative and non-degenerative pathology. This battery evaluates 5 functions, by means of 12 subtests: 1) attention (repetition of digits and numerical key), 2) language (designation of drawings and semantic fluency), 3) visual-espacial / constructive ability (copy a figure and orientation of lines), 4) immediate memory (word learning and memory of the story) and 5) deferred memory (record of the list, word recognition, record of the story, record of the figure). The RBANS is a short battery (time of administration ≦30 minutes), and has two parallel forms of evaluation (forms A and B) to avoid the effect of learning.
19 secondary outcomes
Cardiovascular risk factor: Hypertension.
Time frame: At baseline (at the moment of the study enrollment), and an average of 18 months after enrollment.
Cardiovascular risk factor: Obesity.
Time frame: At baseline (at the moment of the study enrollment), and an average of 18 months after enrollment.
Cardiovascular risk factor: Dyslipidemia.
Time frame: At baseline (at the moment of the study enrollment), and an average of 18 months after enrollment.
Degree of diabetes control.
Time frame: At baseline (at the moment of the study enrollment), at 9 and an average of 18 months after enrollment.
Usal medication.
Time frame: At baseline (at the moment of the study enrollment), and an average of 18 months after enrollment.
Presence of micro and macrovascular complications.
Time frame: At baseline (at the moment of the study enrollment), and an average of 18 months after enrollment.
Presence and severity of hypoglycemia.
Time frame: At baseline (at the moment of the study enrollment), at 4, 9, 13 and an average of 18 months after enrollment.
Lipid profile and renal and hepatic function.
Time frame: At baseline (at the moment of the study enrollment), at 9 and an average of 18 months after enrollment.
Biomarkers (serum and DNA).
Time frame: At baseline (at the moment of the study enrollment), and an average of 18 months after enrollment.
Short Physical Performance Battery test (SPPB).
Time frame: At baseline (at the moment of the study enrollment), and an average of 18 months after enrollment.
Hachinski Scale (HS).
Time frame: At baseline (at the moment of the study enrollment), and an average of 18 months after enrollment.
Blessed Dementia Rating Scale (BDRS).
Time frame: At baseline (at the moment of the study enrollment), at, 4, 9, 13 and an average of 18 months after enrollment.
Geriatric Depression Scale (GDS; 15-item short form).
Time frame: At baseline (at the moment of the study enrollment), at, 4, 9, 13 and an average of 18 months after enrollment.
Schwab and England Activities of Daily Living Scale (SE-ADL).
Time frame: At baseline (at the moment of the study enrollment), at 4, 9, 13 and an average of 18 months after enrollment.
Montreal Cognitive Assessment (MOCA).
Time frame: At baseline (at the moment of the study enrollment), and an average of 18 months after enrollment.
Mini-Mental State Examination (MMSE).
Time frame: At baseline (at the moment of the study enrollment), and an average of 18 months after enrollment.
Memory failure in everyday life questionnaire (MFE).
Time frame: At baseline (at the moment of the study enrollment), at 4, 9, 13 and an average of 18 months after enrollment.
The Functional Social Support Questionnaire (DUKE-UNC-11).
Time frame: At baseline (at the moment of the study enrollment), at 4, 9, 13 and an average of 18 months after enrollment.
The Resource Utilization in Dementia (RUD).
Time frame: At baseline (at the moment of the study enrollment), at 9 and an average of 18 months after enrollment.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Aug 2020.
- Individual participant dataSharing planned: No
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Marco Inzitari, MD, PhD principal investigator
Parc Sanitari Pere Virgili
8 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Smart pillbox and Interactive digital platform in people with Patients Aged 65-85 (Both Included) and Diagnosed of Mild Cognitive Impairment, run by Parc Sanitari Pere Virgili at 8 sites in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 23 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Aug 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 8 sites in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change of score obtained in the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). (time frame: At baseline (at the moment of the study enrollment), and an average of 18 months after enrollment.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Aug 2020.